Literature DB >> 8248132

Ligation of major histocompatibility complex class II molecules mediates apoptotic cell death in resting B lymphocytes.

M K Newell1, J VanderWall, K S Beard, J H Freed.   

Abstract

Class II major histocompatibility complex-encoded molecules expressed on the surface of primed B lymphocytes function as restriction elements for presentation of antigen to T lymphocytes, an interaction that ultimately leads to activation and differentiation of both cell types. The engagement of class II on a resting B cell, on the other hand, inhibits subsequent B-cell growth and activation. Our studies show that treatment of resting B lymphocytes with anti-class II antibodies, or with other agents (dibutyryl cAMP or isoproterenol) that increase intracellular levels of cAMP, results in the apoptotic death of most or all of the resting B cells. Conversely, treating cells with immobilized anti-immunoglobulin and interleukin 4, conditions known to prime cells, protects them from class II-mediated death and specifically from increases in nucleosomal fragments characteristic of apoptotic death. Freshly ex vivo activated B cells likewise are refractory to class II-mediated apoptosis. Treating B cells with anti-class II reagents causes an elevation of cAMP in resting, but not in activated, B cells. These results suggest that apoptotic death is a mechanism of prevention of nonspecific B-cell activation in the event that T-cell receptor and/or CD4 ligation of major histocompatibility complex class II occurs in the absence of antigen.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8248132      PMCID: PMC47796          DOI: 10.1073/pnas.90.22.10459

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  B cells turn off virgin but not memory T cells.

Authors:  E J Fuchs; P Matzinger
Journal:  Science       Date:  1992-11-13       Impact factor: 47.728

2.  Mobility of the human T lymphocyte surface molecules CD3, CD4, and CD8: regulation by a cAMP-dependent pathway.

Authors:  G M Kammer; C A Boehm; S A Rudolph; L A Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

3.  Characterization of cell lines expressing mutant I-Ab and I-Ak molecules allows the definition of distinct serologic epitopes on A alpha and A beta polypeptides.

Authors:  B N Beck; J M Buerstedde; C J Krco; A E Nilson; C G Chase; D J McKean
Journal:  J Immunol       Date:  1986-04-15       Impact factor: 5.422

4.  Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes.

Authors:  K S Sellins; J J Cohen
Journal:  J Immunol       Date:  1987-11-15       Impact factor: 5.422

5.  Properties of monoclonal antibodies to mouse Ig allotypes, H-2, and Ia antigens.

Authors:  V T Oi; P P Jones; J W Goding; L A Herzenberg; L A Herzenberg
Journal:  Curr Top Microbiol Immunol       Date:  1978       Impact factor: 4.291

6.  The role of I-A/E molecules in B lymphocyte activation. I. Inhibition of lipopolysaccharide-induced responses by monoclonal antibodies.

Authors:  S Forsgren; G Pobor; A Coutinho; M Pierres
Journal:  J Immunol       Date:  1984-10       Impact factor: 5.422

7.  Endogenous endonuclease-induced DNA fragmentation: an early event in cell-mediated cytolysis.

Authors:  R C Duke; R Chervenak; J J Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1983-10       Impact factor: 11.205

8.  Ia binding ligands and cAMP stimulate nuclear translocation of PKC in B lymphocytes.

Authors:  J C Cambier; M K Newell; L B Justement; J C McGuire; K L Leach; Z Z Chen
Journal:  Nature       Date:  1987 Jun 18-24       Impact factor: 49.962

9.  Biochemical signals transmitted by Fc gamma receptors: triggering mechanisms of the increased synthesis of adenosine-3',5'-cyclic monophosphate mediated by Fc gamma 2a- and Fc gamma 2b- -receptors of a murine macrophage-like cell line (P388D1).

Authors:  T Nitta; T Suzuki
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

10.  Clonal analysis of B- and T-cell responses to Ia antigens. I. Topology of epitope regions on I-Ak and I-Ek molecules analyzed with 35 monoclonal alloantibodies.

Authors:  M Pierres; C Devaux; M Dosseto; S Marchetto
Journal:  Immunogenetics       Date:  1981-12       Impact factor: 2.846

View more
  22 in total

Review 1.  The role of CD4 in regulating homeostasis of T helper cells.

Authors:  Rolf König; Xiaoli Shen; Rosario Maroto; Timothy L Denning
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 2.  A novel, alternative pathway of apoptosis triggered through class II major histocompatibility complex molecules.

Authors:  Zoltan A Nagy; Nuala A Mooney
Journal:  J Mol Med (Berl)       Date:  2003-10-09       Impact factor: 4.599

3.  MHC class II exacerbates demyelination in vivo independently of T cells.

Authors:  Meenaxi M Hiremath; Vivian S Chen; Kinuko Suzuki; Jenny P Y Ting; Glenn K Matsushima
Journal:  J Neuroimmunol       Date:  2008-10-15       Impact factor: 3.478

4.  MPYS, a novel membrane tetraspanner, is associated with major histocompatibility complex class II and mediates transduction of apoptotic signals.

Authors:  Lei Jin; Paul M Waterman; Karen R Jonscher; Cindy M Short; Nichole A Reisdorph; John C Cambier
Journal:  Mol Cell Biol       Date:  2008-06-16       Impact factor: 4.272

5.  Impaired catecholaminergic signalling of B lymphocytes in patients with chronic rheumatic diseases.

Authors:  M Wahle; S Kölker; A Krause; G R Burmester; C G Baerwald
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

6.  Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.

Authors:  Rhona Stein; Zhengxing Qu; Susan Chen; David Solis; Hans J Hansen; David M Goldenberg
Journal:  Blood       Date:  2006-06-15       Impact factor: 22.113

7.  Differential effects of staphylococcal toxic shock syndrome toxin-1 on B cell apoptosis.

Authors:  M F Hofer; K Newell; R C Duke; P M Schlievert; J H Freed; D Y Leung
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

8.  A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo.

Authors:  P G Schlegel; R Aharoni; Y Chen; J Chen; D Teitelbaum; R Arnon; M Sela; N J Chao
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

9.  Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines.

Authors:  Rhona Stein; Mitchell R Smith; Susan Chen; Maria Zalath; David M Goldenberg
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

10.  A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.

Authors:  Thomas S Lin; Wendy Stock; Huiping Xu; Mitch A Phelps; Margaret S Lucas; Sara K Guster; Bruce R Briggs; Carolyn Cheney; Pierluigi Porcu; Ian W Flinn; Michael R Grever; James T Dalton; John C Byrd
Journal:  Leuk Lymphoma       Date:  2009-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.